Cargando…

Construction of the waaF Subunit and DNA Vaccine Against Escherichia coli in Cow Mastitis and Preliminary Study on Their Immunogenicity

Escherichia coli (E. coli) is one of the major pathogenic bacteria in bovine mastitis, which usually triggers systemic symptoms by releasing lipopolysaccharide (LPS). waaF is the core in LPS pathogenicity. In this study, a new waaF vaccine candidate was identified, constructed with the pcDNA3.1 (+)H...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Hua, Yuan, Ligang, Wang, Tao, Cao, Lu, Liu, Fukang, Song, Juanjuan, Zhang, Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9134013/
https://www.ncbi.nlm.nih.gov/pubmed/35647105
http://dx.doi.org/10.3389/fvets.2022.877685
_version_ 1784713703868858368
author Wang, Hua
Yuan, Ligang
Wang, Tao
Cao, Lu
Liu, Fukang
Song, Juanjuan
Zhang, Yong
author_facet Wang, Hua
Yuan, Ligang
Wang, Tao
Cao, Lu
Liu, Fukang
Song, Juanjuan
Zhang, Yong
author_sort Wang, Hua
collection PubMed
description Escherichia coli (E. coli) is one of the major pathogenic bacteria in bovine mastitis, which usually triggers systemic symptoms by releasing lipopolysaccharide (LPS). waaF is the core in LPS pathogenicity. In this study, a new waaF vaccine candidate was identified, constructed with the pcDNA3.1 (+)HisB-waaF plasmid to create to a DNA vaccine (pcwaaF), and transfected into MCF-7 cells to produce recombinant waaF subunit vaccine (rwaaF). After that, the safety of the two vaccine candidates was evaluated in mouse model. Immunogenicity and mortality of challenged mice were compared in 20 and 40 μg per dose, respectively. The results showed that rwaaF and pcwaaF were successfully constructed and the complete blood count and serum biochemical indicated that both of the vaccine candidates were safe (p > 0.05). In addition, histopathological staining showed no obvious pathological changes. The immune response induced by rwaaF was significantly higher than that of pcwaaF (p < 0.01), indicated by levels of serum concentration of IgG IL-2, IL-4, and IFN-γ, and feces concentration of sIgA. Survival rates of mice in rwaaF groups (both 80%) were also higher than in the pcwaaF groups (40 and 50%, respectively). Comparing the safety, immunogenicity, and E. coli challenge of two vaccine candidates, rwaaF had the better effect and 20 μg rwaaF was more economical. In conclusion, this study demonstrates the utility of a new E. coli vaccine and provides a rationale for further investigation of bovine mastitis therapy and management.
format Online
Article
Text
id pubmed-9134013
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-91340132022-05-27 Construction of the waaF Subunit and DNA Vaccine Against Escherichia coli in Cow Mastitis and Preliminary Study on Their Immunogenicity Wang, Hua Yuan, Ligang Wang, Tao Cao, Lu Liu, Fukang Song, Juanjuan Zhang, Yong Front Vet Sci Veterinary Science Escherichia coli (E. coli) is one of the major pathogenic bacteria in bovine mastitis, which usually triggers systemic symptoms by releasing lipopolysaccharide (LPS). waaF is the core in LPS pathogenicity. In this study, a new waaF vaccine candidate was identified, constructed with the pcDNA3.1 (+)HisB-waaF plasmid to create to a DNA vaccine (pcwaaF), and transfected into MCF-7 cells to produce recombinant waaF subunit vaccine (rwaaF). After that, the safety of the two vaccine candidates was evaluated in mouse model. Immunogenicity and mortality of challenged mice were compared in 20 and 40 μg per dose, respectively. The results showed that rwaaF and pcwaaF were successfully constructed and the complete blood count and serum biochemical indicated that both of the vaccine candidates were safe (p > 0.05). In addition, histopathological staining showed no obvious pathological changes. The immune response induced by rwaaF was significantly higher than that of pcwaaF (p < 0.01), indicated by levels of serum concentration of IgG IL-2, IL-4, and IFN-γ, and feces concentration of sIgA. Survival rates of mice in rwaaF groups (both 80%) were also higher than in the pcwaaF groups (40 and 50%, respectively). Comparing the safety, immunogenicity, and E. coli challenge of two vaccine candidates, rwaaF had the better effect and 20 μg rwaaF was more economical. In conclusion, this study demonstrates the utility of a new E. coli vaccine and provides a rationale for further investigation of bovine mastitis therapy and management. Frontiers Media S.A. 2022-05-12 /pmc/articles/PMC9134013/ /pubmed/35647105 http://dx.doi.org/10.3389/fvets.2022.877685 Text en Copyright © 2022 Wang, Yuan, Wang, Cao, Liu, Song and Zhang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Veterinary Science
Wang, Hua
Yuan, Ligang
Wang, Tao
Cao, Lu
Liu, Fukang
Song, Juanjuan
Zhang, Yong
Construction of the waaF Subunit and DNA Vaccine Against Escherichia coli in Cow Mastitis and Preliminary Study on Their Immunogenicity
title Construction of the waaF Subunit and DNA Vaccine Against Escherichia coli in Cow Mastitis and Preliminary Study on Their Immunogenicity
title_full Construction of the waaF Subunit and DNA Vaccine Against Escherichia coli in Cow Mastitis and Preliminary Study on Their Immunogenicity
title_fullStr Construction of the waaF Subunit and DNA Vaccine Against Escherichia coli in Cow Mastitis and Preliminary Study on Their Immunogenicity
title_full_unstemmed Construction of the waaF Subunit and DNA Vaccine Against Escherichia coli in Cow Mastitis and Preliminary Study on Their Immunogenicity
title_short Construction of the waaF Subunit and DNA Vaccine Against Escherichia coli in Cow Mastitis and Preliminary Study on Their Immunogenicity
title_sort construction of the waaf subunit and dna vaccine against escherichia coli in cow mastitis and preliminary study on their immunogenicity
topic Veterinary Science
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9134013/
https://www.ncbi.nlm.nih.gov/pubmed/35647105
http://dx.doi.org/10.3389/fvets.2022.877685
work_keys_str_mv AT wanghua constructionofthewaafsubunitanddnavaccineagainstescherichiacoliincowmastitisandpreliminarystudyontheirimmunogenicity
AT yuanligang constructionofthewaafsubunitanddnavaccineagainstescherichiacoliincowmastitisandpreliminarystudyontheirimmunogenicity
AT wangtao constructionofthewaafsubunitanddnavaccineagainstescherichiacoliincowmastitisandpreliminarystudyontheirimmunogenicity
AT caolu constructionofthewaafsubunitanddnavaccineagainstescherichiacoliincowmastitisandpreliminarystudyontheirimmunogenicity
AT liufukang constructionofthewaafsubunitanddnavaccineagainstescherichiacoliincowmastitisandpreliminarystudyontheirimmunogenicity
AT songjuanjuan constructionofthewaafsubunitanddnavaccineagainstescherichiacoliincowmastitisandpreliminarystudyontheirimmunogenicity
AT zhangyong constructionofthewaafsubunitanddnavaccineagainstescherichiacoliincowmastitisandpreliminarystudyontheirimmunogenicity